Newsroom

Newsroom

Featured News

Date Title and Summary
Toggle Summary Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
Additional Detail in Patients Age 50 or Younger Presented Today in Oral Session at 2019 American Society of Clinical Oncology ( ASCO ) Annual Meeting TAILORx Continues to Elevate Oncotype DX ® to a New Global Standard with Increasing Utilization and Reimbursement REDWOOD CITY, Calif.
Toggle Summary Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer
New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial to be Presented at ASCO Annual Meeting Today REDWOOD CITY, Calif.
Toggle Summary Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
Results, Published in Urology, Represent First Prospective Validation of Critical Endpoint to Identify Patients for Active Surveillance REDWOOD CITY, Calif. , Feb. 5, 2019 /PRNewswire/ --  Genomic Health, Inc . (Nasdaq: GHDX) today announced the publication of results from a multi-center,
Toggle Summary Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
Pioneering Precision Medicine While Saving Healthcare Costs REDWOOD CITY, Calif. , Jan. 7, 2019 /PRNewswire/ --  Genomic Health , Inc.  (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million Oncotype DX ® tests to cancer patients

Latest Press Releases

Date Title and Summary
Toggle Summary New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
- Guidelines include TAILORx-defined cutoff of 26 for determining chemotherapy benefit in node-negative disease, and recommend that more women with limited nodal involvement may avoid chemotherapy - Oncotype DX® test recommended based on prospective landmark TAILORx and German PlanB studies,
Toggle Summary Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
Delivered $114.1M in Revenue and Growth of 19.4% in the Second Quarter Reported $16.0M in Profit and EPS of $0.42 Per Share on a Diluted Basis Raises Full-Year 2019 Revenue and Net Income Guidance Earnings Call and Webcast Previously Scheduled for Thursday, August 1 Will Now Occur Today Monday,
Toggle Summary Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-class commercial, research, development and clinical organization, with enhanced scale and scope in cancer diagnostics Global infrastructure
Toggle Summary Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
REDWOOD CITY, Calif. , July 25, 2019 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2019 financial results.

Patient & Physician Stories

 

 
 

Your Prostate, Your Decision: A Patient's Perspective

1559 views 09/24/2014

Watch the Video

Do You Know Your Oncotype DX Score?

174 views 09/29/2015

Watch the Video

Oncotype DX DCIS Breast Cancer Score: Amy's Story

8370 views 07/17/2013

Watch the Video

An Oncotype DX Breast Cancer Treatment Story from Mexico (MX)

644 views 11/13/2012

Watch the Video

Dr. Peter Carroll on the Validation of the Oncotype DX Prostate Cancer Test

299 views 12/08/2015

Watch the Video

Dr. Joseph Sparano on the Necessity of Oncotype DX Genomic Testing in Breast Cancer

164 views 12/08/2015

Watch the Video

 

Social Media

Learn About the Oncotype DX Prostate Cancer Test

13600 views 05/04/2013

Watch the Video

Genomic Health and Oncotype IQ – Delivering Precision Medicine

67 views 09/06/2018

Watch the Video

Oncotype DX AR-V7 Nucleus Detect test

528 views 08/10/2018

Watch the Video